Peter Kuhn, PhD

University Professor, Dean's Professor of Biological Sciences and Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace and Mechanical Engineering and Urology

Image of Peter Kuhn, PhD
Is this your profile? Click to edit

Overview

Peter Kuhn joined the USC Dana and David Dornsife College of Letters, Arts and Sciences as Dean’s Professor of Biological Sciences in July 2014. Dr. Kuhn also has appointments as Professor of Medicine, Professor of Biomedical Engineering and Professor of Aerospace & Mechanical Engineering, a founding member of the Michelson Center for Convergent Biosciences at USC and is leading CSI-Cancer at USC. He is a scientist, educator and entrepreneur with a career long commitment in personalized medicine and individualized cancer patient care. He is focused on the redesign of cancer care. The first product from technology developed by Dr. Kuhn became available for prostate cancer care in June 2016. Dr. Kuhn’s strategy is to advance our understanding of the human body to improve the human condition for those affected by cancer. His research is shedding new light at how cancer spreads through the body and evolves over time. This new science will lead to a personalized care strategy that is biologically informed and clinically actionable. He is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 and his Ph.D. in 1995. He then moved to Stanford University where he joined the faculties of Medicine and Accelerator Physics as tenure track Assistant Professor. From 2002 to 2014 he established the Physics Oncology program at The Scripps Research in La Jolla, CA as tenured Associate Professor before joining USC in 2014. He has published over 200 peer scientific articles and patents resulting from his research.

Publications

  • Selective removal of proteins and microvesicles ex vivo from blood of pancreatic cancer patients using bioengineered adsorption filters. Cancer Lett. 2025 Apr 01; 614:217546.. View in PubMed
  • Cells in the Polyaneuploid Cancer Cell State Are Prometastatic. Mol Cancer Res. 2025 03 03; 23(3):219-235.. View in PubMed
  • Polyploid cancer cells reveal signatures of chemotherapy resistance. Oncogene. 2025 Mar; 44(7):439-449.. View in PubMed
  • Unsupervised Detection of Rare Events in Liquid Biopsy Assays. bioRxiv. 2025 Jan 31.. View in PubMed
  • Single-cell somatic copy number alteration profiling of vitreous humor seeds in retinoblastoma. Ophthalmic Genet. 2024 12; 45(6):646-649.. View in PubMed
  • Multi-Omic Characterization of Single Cells and Cell-Free Components Detected in the Cerebrospinal Fluid of Patients with Leptomeningeal Disease. Cancers (Basel). 2024 Nov 06; 16(22).. View in PubMed
  • Phenotypic Biomarkers of Aqueous Extracellular Vesicles from Retinoblastoma Eyes. Int J Mol Sci. 2024 Oct 30; 25(21).. View in PubMed
  • Polyploid cancer cells reveal signatures of chemotherapy resistance. Res Sq. 2024 Oct 14.. View in PubMed
  • Circulation of rare events in the liquid biopsy for early detection of lung mass lesions. Thorac Cancer. 2024 10; 15(29):2100-2109.. View in PubMed
  • Lexicon for blood-based early detection and screening: BLOODPAC consensus document. Clin Transl Sci. 2024 Sep; 17(9):e70016.. View in PubMed